Article History
Accepted: 9 December 2021
First Online: 25 February 2022
Declarations
:
: No specific funding was received for this work.
: Margherita Fabbri declares the following conflicts of interest: honoraria to speak: BIAL and AbbVie. Joaquim J. Ferreira declares the following conflicts of interest: consultancy for BIAL and principal investigator of the BIPARK I study; stock ownership in medically related fields: none; consultancies: Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, Merck-Serono, and Merz; advisory boards: none; partnership: none; honoraria to speak: none; grants: GlaxoSmithKline, Grunenthal, Teva, and Fundação MSD. Olivier Rascol declares the following conflicts of interest: advisory board and consultancy: BIAL; advisory boards and consultancy: AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Axovant, Biogen, Britannia, Buckwang, Cerespir, Clevexel, Denali, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Théranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, and Zambon; grant: Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020), and Cure Parkinson IK; other: grant to participate in a symposium and contribute to the review of an IPMDS article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All co-authors have been substantially involved in the preparation of the manuscript; all the co-authors have also seen and approved the final submitted version and agreed to be accountable for the work. 1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique. MF: 1A, 1B, 1C, 3A; JJF: 1A, 1B, 3B; OR: 1A, 2A, 3B.